285 related articles for article (PubMed ID: 23319187)
1. Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features.
Karsy M; Gelbman M; Shah P; Balumbu O; Moy F; Arslan E
Folia Neuropathol; 2012; 50(4):301-21. PubMed ID: 23319187
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma.
Miller CR; Perry A
Arch Pathol Lab Med; 2007 Mar; 131(3):397-406. PubMed ID: 17516742
[TBL] [Abstract][Full Text] [Related]
3. [Morphological classification of glioblastomas].
Figarella-Branger D; Bouvier C; Moroch J; Michalak S; F Burel-Vandenbos
Neurochirurgie; 2010 Dec; 56(6):459-63. PubMed ID: 20864138
[TBL] [Abstract][Full Text] [Related]
4. Treatment and survival of patients harboring histological variants of glioblastoma.
Ortega A; Nuño M; Walia S; Mukherjee D; Black KL; Patil CG
J Clin Neurosci; 2014 Oct; 21(10):1709-13. PubMed ID: 24980627
[TBL] [Abstract][Full Text] [Related]
5. New insights into the genetics of glioblastoma multiforme by familial exome sequencing.
Backes C; Harz C; Fischer U; Schmitt J; Ludwig N; Petersen BS; Mueller SC; Kim YJ; Wolf NM; Katus HA; Meder B; Furtwängler R; Franke A; Bohle R; Henn W; Graf N; Keller A; Meese E
Oncotarget; 2015 Mar; 6(8):5918-31. PubMed ID: 25537509
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
[TBL] [Abstract][Full Text] [Related]
7. Glioblastomas with an oligodendroglial component: a pathological and molecular study.
He J; Mokhtari K; Sanson M; Marie Y; Kujas M; Huguet S; Leuraud P; Capelle L; Delattre JY; Poirier J; Hoang-Xuan K
J Neuropathol Exp Neurol; 2001 Sep; 60(9):863-71. PubMed ID: 11556543
[TBL] [Abstract][Full Text] [Related]
8. Molecular, histopathological, and genomic variants of glioblastoma.
Karsy M; Huang T; Kleinman G; Karpel-Massler G
Front Biosci (Landmark Ed); 2014 Jun; 19(7):1065-87. PubMed ID: 24896337
[TBL] [Abstract][Full Text] [Related]
9. Molecular and Genomic Alterations in Glioblastoma Multiforme.
Crespo I; Vital AL; Gonzalez-Tablas M; Patino Mdel C; Otero A; Lopes MC; de Oliveira C; Domingues P; Orfao A; Tabernero MD
Am J Pathol; 2015 Jul; 185(7):1820-33. PubMed ID: 25976245
[TBL] [Abstract][Full Text] [Related]
10. Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification.
Li B; Senbabaoglu Y; Peng W; Yang ML; Xu J; Li JZ
Clin Cancer Res; 2012 Oct; 18(20):5595-605. PubMed ID: 22912392
[TBL] [Abstract][Full Text] [Related]
11. The landscape of the mesenchymal signature in brain tumours.
Behnan J; Finocchiaro G; Hanna G
Brain; 2019 Apr; 142(4):847-866. PubMed ID: 30946477
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results.
Galanis E; Buckner JC; Dinapoli RP; Scheithauer BW; Jenkins RB; Wang CH; O'Fallon JR; Farr G
J Neurosurg; 1998 Sep; 89(3):425-30. PubMed ID: 9724117
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme.
Liang Y; Diehn M; Watson N; Bollen AW; Aldape KD; Nicholas MK; Lamborn KR; Berger MS; Botstein D; Brown PO; Israel MA
Proc Natl Acad Sci U S A; 2005 Apr; 102(16):5814-9. PubMed ID: 15827123
[TBL] [Abstract][Full Text] [Related]
14. Chromogenic in situ hybridization accurately identifies EGFR amplification in small cell glioblastoma multiforme, a common subtype of primary GBM.
Quezado M; Ronchetti R; Rapkiewicz A; Santi M; Blumenthal DT; Rushing EJ
Clin Neuropathol; 2005; 24(4):163-9. PubMed ID: 16033132
[TBL] [Abstract][Full Text] [Related]
15. Molecular and clinical analysis of glioblastoma with an oligodendroglial component (GBMO).
Nakamura H; Makino K; Kuratsu J
Brain Tumor Pathol; 2011 Jul; 28(3):185-90. PubMed ID: 21629979
[TBL] [Abstract][Full Text] [Related]
16. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
17. Stem cell signature in glioblastoma: therapeutic development for a moving target.
Nakano I
J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
[TBL] [Abstract][Full Text] [Related]
18. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
20. Genetic analysis of a case of glioblastoma with oligodendroglial component arising during the progression of diffuse astrocytoma.
Hata N; Suzuki SO; Murata H; Hatae R; Akagi Y; Sangatsuda Y; Amano T; Yoshimoto K; Tahira T; Mizoguchi M
Pathol Oncol Res; 2015 Jul; 21(3):839-43. PubMed ID: 25354913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
